09:56:50 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-12 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-20 Ordinarie utdelning SCIB 0.00 SEK
2024-05-17 Årsstämma 2024
2024-05-09 Kvartalsrapport 2024-Q1
2024-02-22 Bokslutskommuniké 2023
2023-11-10 Kvartalsrapport 2023-Q3
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-19 Ordinarie utdelning SCIB 0.00 SEK
2023-05-17 Årsstämma 2023
2023-05-10 Kvartalsrapport 2023-Q1
2023-02-13 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning SCIB 0.00 SEK
2022-05-18 Årsstämma 2022
2022-05-12 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-09-07 Extra Bolagsstämma 2021
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-19 Ordinarie utdelning SCIB 0.00 SEK
2021-05-18 Årsstämma 2021
2021-05-12 Kvartalsrapport 2021-Q1
2021-02-19 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-17 Årsstämma 2020
2020-05-15 Ordinarie utdelning SCIB 0.00 SEK
2020-05-05 Kvartalsrapport 2020-Q1
2020-04-29 Extra Bolagsstämma 2020
2020-02-21 Bokslutskommuniké 2019
2019-11-13 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-17 Ordinarie utdelning SCIB 0.00 SEK
2019-05-16 Årsstämma 2019
2019-05-10 Kvartalsrapport 2019-Q1
2019-02-20 Bokslutskommuniké 2018
2018-11-13 Kvartalsrapport 2018-Q3
2018-08-20 Kvartalsrapport 2018-Q2
2018-05-17 Ordinarie utdelning SCIB 0.00 SEK
2018-05-16 Årsstämma 2018
2018-05-09 Kvartalsrapport 2018-Q1
2018-02-20 Bokslutskommuniké 2017
2017-11-15 Extra Bolagsstämma 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-08-18 Kvartalsrapport 2017-Q2
2017-05-17 Ordinarie utdelning SCIB 0.00 SEK
2017-05-16 Årsstämma 2017
2017-05-10 Kvartalsrapport 2017-Q1
2017-02-17 Bokslutskommuniké 2016
2016-11-14 Kvartalsrapport 2016-Q3
2016-08-19 Kvartalsrapport 2016-Q2
2016-05-17 Ordinarie utdelning SCIB 0.00 SEK
2016-05-16 Årsstämma 2016
2016-05-13 Kvartalsrapport 2016-Q1
2016-02-19 Bokslutskommuniké 2015
2015-11-12 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2015-05-06 Kvartalsrapport 2015-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
SciBase Holding är verksamt inom medicinteknik. Koncernen är specialiserad inom hantering av cancerdiagnostik, främst inriktat mot behandling och upptäckandet av diverse melanom. Bolaget har utvecklat en elektrisk handhållen sond som analyserar mätsignalen för att upptäcka specifika förändringar i kroppens hudvävnad. Huvudkontoret ligger i Stockholm.
2021-11-05 15:00:00

SciBase a leading developer of augmented intelligence-based solutions for skin disorders, announced today that CFO Michael Colérus will present an update on the latest developments from SciBase at the Redeye Life Science day on November11[th] at 16.10 pm. The presentation will be followed by a short Q&A. The presentation will be broadcasted live and can be followed at https://www.redeye.se/events/815899/redeye-life-science-day-2021 The presentation will also be available at www.redeye.se and on the Company's website i n Redeye Universe.

"We have achieved many exciting and important milestones recently at SciBase. After a long process we received our MDR-certification which enabled us to launch our NMSC (non-melanoma skin cancer) application in Europe, which is a key part of our growth strategy. We have also entered a new phase in the US by submitting our first application for reimbursement coverage - another very important milestone for the company. Within the skin barrier application two significant and groundbreaking clinical studies have recently been published. The skin barrier is an exciting new application area for SciBase and one where we have unique advantages. Barrier-related diseases are widespread and using Nevisense as a tool for the assessment of the barrier can really help better understand and manage patients," says Simon Grant, CEO SciBase.

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com 

Certified Advisor:
Vator Securities
Tel: +46 8 580 065 99
Email: ca@vatorsec.se  

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.